在Bai高血压人口中探索CYP2D6多态性和血管激素受体阻塞反应
Canbiao Yang1, Guoqiang Zhang2, Chang Shu3
1Dali First People's Hospital, Yunnan.
Pharmacogenetics and genomics
|June 7, 2024
概括
某些CYP2D6基因变异显著影响了血管激素受体抑制剂 (ARB) 在中国白病患者的高血压治疗效果. 特定突变改善了血压控制和治疗成功率,为个性化医疗铺平了道路.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
背景情况:
- 细胞染色体P450 2D6 (CYP2D6) 酶对于药物代谢至关重要.
- 在CYP2D6的遗传变异可以改变药物反应.
- 高血压管理通常涉及血管激素受体抑制剂 (ARBs).
研究的目的:
- 为了研究CYP2D6基因多态性和ARB治疗响应在患有高血压的中国Bai个体之间的关联.
- 为了确定特定的CYP2D6基因型是否影响降低血压和治疗疗效.
主要方法:
- 招募了72名患有高血压的中国白族成年人.
- 针对性区域测序用于基因型CYP2D6单核酸多态 (SNP).
- 评估了基因型对ARB疗效的影响.
主要成果:
- 九个显著的CYP2D6多态性与ARB治疗疗效相关.
- 在rs111564371的突变显著降低了静缩和静缩血压 (p=0.021,p=0.016).
- 在rs111564371和rs112568578的突变基因型与~20%更高的疗效和10%更高的目标实现率相关联.
结论:
- 特定的CYP2D6多态性显著影响高血压的中国白病患者的ARB治疗结果.
- 突变,特别是在rs111564371,增强血压控制和ARB疗效.
- 这些发现支持药物基因组学在定制高血压治疗以改善患者护理方面的作用.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
711
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
711
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
617
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617
01:25Antihypertensive Drugs: Direct Renin Inhibitors
585
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
585
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:17Antihypertensive Drugs: Action of β1 Blockers
427
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
427
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
432
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
432